The Wilms’ tumor gene WT1-GFP knock-in mouse reveals the dynamic regulation of WT1 expression in normal and leukemic hematopoiesis (original) (raw)

• Call KM, Glaser T, Ito CY, Buckler AJ, Pelletier J, Haber DA et al. Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms’ tumor locus. Cell 1990; 60: 509–520.
  Article CAS PubMed Google Scholar
• Gessler M, Poustka A, Cavenee W, Neve RL, Orkin SH, Bruns GA . Homozygous deletion in Wilms tumours of a zinc-finger gene identified by chromosome jumping. Nature 1990; 343: 774–778.
  Article CAS PubMed Google Scholar
• Inoue K, Sugiyama H, Ogawa H, Nakagawa M, Yamagami T, Miwa H et al. WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. Blood 1994; 84: 3071–3079.
  CAS PubMed Google Scholar
• Bergmann L, Miething C, Maurer U, Brieger J, Karakas T, Weidmann E et al. High levels of Wilms’ tumor gene (wt1) mRNA in acute myeloid leukemias are associated with a worse long-term outcome. Blood 1997; 90: 1217–1225.
  CAS PubMed Google Scholar
• Miwa H, Beran M, Saunders GF . Expression of the Wilms’ tumor gene (WT1) in human leukemias. Leukemia 1992; 6: 405–409.
  CAS PubMed Google Scholar
• Menssen HD, Renkl HJ, Rodeck U, Maurer J, Notter M, Schwartz S et al. Presence of Wilms’ tumor gene (wt1) transcripts and the WT1 nuclear protein in the majority of human acute leukemias. Leukemia 1995; 9: 1060–1067.
  CAS PubMed Google Scholar
• King-Underwood L, Renshaw J, Pritchard-Jones K . Mutations in the Wilms’ tumor gene WT1 in leukemias. Blood 1996; 87: 2171–2179.
  CAS PubMed Google Scholar
• King-Underwood L, Pritchard-Jones K . Wilms’ tumor (WT1) gene mutations occur mainly in acute myeloid leukemia and may confer drug resistance. Blood 1998; 91: 2961–2968.
  CAS PubMed Google Scholar
• Ogawa H, Tamaki H, Ikegame K, Soma T, Kawakami M, Tsuboi A et al. The usefulness of monitoring WT1 gene transcripts for the prediction and management of relapse following allogeneic stem cell transplantation in acute type leukemia. Blood 2003; 101: 1698–1704.
  Article CAS PubMed Google Scholar
• Lapillonne H, Renneville A, Auvrignon A, Flamant C, Blaise A, Perot C et al. High WT1 expression after induction therapy predicts high risk of relapse and death in pediatric acute myeloid leukemia. J Clin Oncol 2006; 24: 1507–1515.
  Article CAS PubMed Google Scholar
• Cilloni D, Gottardi E, De Micheli D, Serra A, Volpe G, Messa F et al. Quantitative assessment of WT1 expression by real time quantitative PCR may be a useful tool for monitoring minimal residual disease in acute leukemia patients. Leukemia 2002; 16: 2115–2121.
  Article CAS PubMed Google Scholar
• Kreuzer KA, Saborowski A, Lupberger J, Appelt C, Na IK, le Coutre P et al. Fluorescent 5′-exonuclease assay for the absolute quantification of Wilms’ tumour gene (WT1) mRNA: implications for monitoring human leukaemias. Br J Haematol 2001; 114: 313–318.
  Article CAS PubMed Google Scholar
• Ohminami H, Yasukawa M, Fujita S . HLA class I-restricted lysis of leukemia cells by a CD8(+) cytotoxic T-lymphocyte clone specific for WT1 peptide. Blood 2000; 95: 286–293.
  CAS PubMed Google Scholar
• Gao L, Bellantuono I, Elsasser A, Marley SB, Gordon MY, Goldman JM et al. Selective elimination of leukemic CD34(+) progenitor cells by cytotoxic T lymphocytes specific for WT1. Blood 2000; 95: 2198–2203.
  CAS PubMed Google Scholar
• Gaiger A, Reese V, Disis ML, Cheever MA . Immunity to WT1 in the animal model and in patients with acute myeloid leukemia. Blood 2000; 96: 1480–1489.
  CAS PubMed Google Scholar
• Oka Y, Udaka K, Tsuboi A, Elisseeva OA, Ogawa H, Aozasa K et al. Cancer immunotherapy targeting Wilms’ tumor gene WT1 product. J Immunol 2000; 164: 1873–1880.
  Article CAS PubMed Google Scholar
• Oka Y, Tsuboi A, Taguchi T, Osaki T, Kyo T, Nakajima H et al. Induction of WT1 (Wilms’ tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc Natl Acad Sci USA 2004; 101: 13885–13890.
  Article CAS PubMed PubMed Central Google Scholar
• Oka Y, Tsuboi A, Murakami M, Hirai M, Tominaga N, Nakajima H et al. Wilms tumor gene peptide-based immunotherapy for patients with overt leukemia from myelodysplastic syndrome (MDS) or MDS with myelofibrosis. Int J Hematol 2003; 78: 56–61.
  Article CAS PubMed Google Scholar
• Mailander V, Scheibenbogen C, Thiel E, Letsch A, Blau IW, Keilholz U . Complete remission in a patient with recurrent acute myeloid leukemia induced by vaccination with WT1 peptide in the absence of hematological or renal toxicity. Leukemia 2004; 18: 165–166.
  Article CAS PubMed Google Scholar
• Hosen N, Sonoda Y, Oji Y, Kimura T, Minamiguchi H, Tamaki H et al. Very low frequencies of human normal CD34+ haematopoietic progenitor cells express the Wilms’ tumour gene WT1 at levels similar to those in leukaemia cells. Br J Haematol 2002; 116: 409–420.
  Article CAS PubMed Google Scholar
• Haber DA, Sohn RL, Buckler AJ, Pelletier J, Call KM, Housman DE . Alternative splicing and genomic structure of the Wilms tumor gene WT1. Proc Natl Acad Sci USA 1991; 88: 9618–9622.
  Article CAS PubMed PubMed Central Google Scholar
• Kreidberg JA, Sariola H, Loring JM, Maeda M, Pelletier J, Housman D et al. WT-1 is required for early kidney development. Cell 1993; 74: 679–691.
  Article CAS PubMed Google Scholar
• Christensen JL, Weissman IL . Flk-2 is a marker in hematopoietic stem cell differentiation: a simple method to isolate long-term stem cells. Proc Natl Acad Sci USA 2001; 98: 14541–14546.
  Article CAS PubMed PubMed Central Google Scholar
• Akashi K, Traver D, Miyamoto T, Weissman IL . A clonogenic common myeloid progenitor that give rise to all myeloid lineages. Nature 2000; 404: 193–197.
  Article CAS PubMed Google Scholar
• Grisolano JL, O'Neal J, Cain J, Tomasson MH . An activated receptor tyrosine kinase, TEL/PDGF_β_R, cooperates with AML1/ETO to induce acute myeloid leukemia in mice. Proc Natl Acad Sci USA 2003; 100: 9506–9511.
  Article CAS PubMed PubMed Central Google Scholar
• Pear WS, Miller JP, Xu L, Pui JC, Soffer B, Quackenbush RC et al. Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving p210 bcr/abl-transduced bone marrow. Blood 1998; 92: 3780–3792.
  CAS PubMed Google Scholar
• Zhang X, Ren R . Bcr-Abl efficiently induces a myeloproliferative disease and production of excess interleukin-3 and granulocyte-macrophage colony-stimulating factor in mice: a novel model for chronic myelogenous leukemia. Blood 1998; 92: 3829–3840.
  CAS PubMed Google Scholar
• Goldman JP, Blundell MP, Lopes L, Kinnon C, Di Santo JP, Thrasher AJ et al. Enhanced human cell engraftment in mice deficient in RAG2 and the common cytokine receptor gamma chain. Br J Haematol 1998; 103: 335–342.
  Article CAS PubMed Google Scholar
• Menssen HD, Renkl HJ, Entezami M, Thiel E . Wilms’ tumor gene expression in human CD34+ hematopoietic progenitors during fetal development and early clonogenic growth. Blood 1997; 89: 3486–3487.
  CAS PubMed Google Scholar
• Morrison SJ, Hemmati HD, Wandycz AM, Weissman IL . The purification and characterization of fetal liver hematopoietic stem cells. Proc Natl Acad Sci USA 1995; 92: 10302–10306.
  Article CAS PubMed PubMed Central Google Scholar
• Passegue E, Wagers AJ, Giuriato S, Anderson WC, Weissman IL . Global analysis of proliferation and cell cycle gene expression in the regulation of hematopoietic stem and progenitor cell fates. J Exp Med 2005; 202: 1599–1611.
  Article CAS PubMed PubMed Central Google Scholar
• Spangrude GJ, Heimfeld S, Weissman IL . Purification and characterization of mouse hematopoietic stem cells. Science 1988; 241: 58–62.
  Article CAS PubMed Google Scholar
• Oji Y, Miyoshi S, Maeda H, Hayashi S, Tamaki H, Nakatsuka S et al. Overexpression of the Wilms’ tumor gene WT1 in de novo lung cancers. Int J Cancer 2002; 100: 297–303.
  Article CAS PubMed Google Scholar
• Oji Y, Yamamoto H, Nomura M, Nakano Y, Ikeba A, Nakatsuka S et al. Overexpression of the Wilms’ tumor gene WT1 in colorectal adenocarcinoma. Cancer Sci 2003; 94: 712–717.
  Article CAS PubMed Google Scholar
• Pelletier J, Bruening W, Li FP, Haber DA, Glaser T, Housman DE . WT1 mutations contribute to abnormal genital system development and hereditary Wilms’ tumour. Nature 1991; 353: 431–434.
  Article CAS PubMed Google Scholar
• Wagner KD, Wagner N, Vidal VP, Schley G, Wilhelm D, Schedl A et al. The Wilms’ tumor gene Wt1 is required for normal development of the retina. EMBO J 2002; 21: 1398–1405.
  Article CAS PubMed PubMed Central Google Scholar
• Wagner KD, Wagner N, Bondke A, Nafz B, Flemming B, Theres H et al. The Wilms’ tumor suppressor Wt1 is expressed in the coronary vasculature after myocardial infarction. FASEB J 2002; 16: 1117–1119.
  Article CAS PubMed Google Scholar
• Moore AW, Schedl A, McInnes L, Doyle M, Hecksher-Sorensen J, Hastie ND . YAC transgenic analysis reveals Wilms’ tumour 1 gene activity in the proliferating coelomic epithelium, developing diaphragm and limb. Mech Dev 1998; 79: 169–184.
  Article CAS PubMed Google Scholar
• Kanato K, Hosen N, Yanagihara M, Nakagata N, Shirakata T, Nakazawa T et al. The Wilms’ tumor gene WT1 is a common marker of progenitor cells in fetal liver. Biochem Biophys Res Commun 2005; 326: 836–843.
  Article CAS PubMed Google Scholar
• Alberta JA, Springett GM, Rayburn H, Natoli TA, Loring J, Kreidberg JA et al. Role of the WT1 tumor suppressor in murine hematopoiesis. Blood 2003; 101: 2570–2574.
  Article CAS PubMed Google Scholar
• Bonnet D, Dick JE . Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997; 3: 730–737.
  Article CAS PubMed Google Scholar
• Baum CM, Weissman IL, Tsukamoto AS, Buckle AM, Peault B . Isolation of a candidate human hematopoietic stem-cell population. Proc Natl Acad Sci USA 1992; 89: 2804–2808.
  Article CAS PubMed PubMed Central Google Scholar
• Blair A, Hogge DE, Ailles LE, Lansdorp PM, Sutherland HJ . Lack of expression of Thy-1 (CD90) on acute myeloid leukemia cells with long-term proliferative ability in vitro and in vivo. Blood 1997; 89: 3104–3112.
  CAS PubMed Google Scholar
• Miyamoto T, Weissman IL, Akashi K . AML1/ETO-expressing nonleukemic stem cells in acute myelogenous leukemia with 8:21 chromosomal translocation. Proc Natl Acad Sci USA 2000; 97: 7521–7526.
  Article CAS PubMed PubMed Central Google Scholar
• Inoue K, Ogawa H, Sonoda Y, Kimura T, Sakabe H, Oka Y et al. Aberrant overexpression of the Wilms tumor gene (WT1) in human leukemia. Blood 1997; 89: 1405–1412.
  CAS PubMed Google Scholar
• Svedberg H, Richter J, Gullberg U . Forced expression of the Wilms tumor 1 (WT1) gene inhibits proliferation of human hematopoietic CD34(+) progenitor cells. Leukemia 2001; 15: 914–922.
  Article Google Scholar
• Ellisen LW, Carlesso N, Cheng T, Scadden DT, Haber DA . The Wilms tumor suppressor WT1 directs stage-specific quiescence and differentiation of human hematopoietic progenitor cells. EMBO J 2001; 17: 1897–1909.
  Article Google Scholar
• Nishida S, Hosen N, Shirakata T, Kanato K, Yanagihara M, Nakatsuka S et al. AML1-ETO rapidly induces acute myeloblastic leukemia in cooperation with the Wilms tumor gene, WT1. Blood 2006; 107: 3303–3312.
  Article CAS PubMed Google Scholar